Background: Omalizumab therapy is effective and safe in patients with chronic spontaneous urticaria (CSU) resistant to nonsedating histamine1 (H1) antihistamines (nsAHs). Objective: To evaluate the efficacy and safety of omalizumab in elderly (aged ≥65 years) patients with nonsedating H1-antihistamine–refractory CSU in a real-life setting. Methods: Patients with nonsedating H1-antihistamine–refractory CSU (n=322) treated with omalizumab administered every 4 weeks in doses of 300mg for 24 weeks were divided into 2 groups according to age atomalizumabtreatmentonset:15to64yearsand65yearsorolder.Treatmentresponsewasassessedusing a 7-day urticaria activity score (UAS7). Adverse effects of omalizumab therapy were recorded. Results: Among patients, 32 (9.9%) were 65 years or older. At baseline, CSU characteristics were generally similar among the groups, although the presence of angioedema was statistically significantly lower in patients younger than 65 years. Any differences in weekly itch severity score, hive score, and UAS7 between the2agegroupswerenotsignificantatweeks4,12,and24,withtheexceptionof thehivescoreat24weeks and the UAS7 at week 24. No significant between-group differences were seen in the proportion of patients with a UAS7 of 6 or lower and with a UAS7 score of 0 at weeks 4, 12, 24, and 40. The proportion of patients with at least one adverse event reported as suspected to be caused by study drug was 10% in the younger group vs 6.3% in the older group (P=.53). Conclusion: Our study found that omalizumab is a well-tolerated and effective therapy for elderly patients with nonsedating H1-antihistamine–refractory CSU.

Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response.

Lodi Rizzini F
Membro del Collaboration Group
;
2018-01-01

Abstract

Background: Omalizumab therapy is effective and safe in patients with chronic spontaneous urticaria (CSU) resistant to nonsedating histamine1 (H1) antihistamines (nsAHs). Objective: To evaluate the efficacy and safety of omalizumab in elderly (aged ≥65 years) patients with nonsedating H1-antihistamine–refractory CSU in a real-life setting. Methods: Patients with nonsedating H1-antihistamine–refractory CSU (n=322) treated with omalizumab administered every 4 weeks in doses of 300mg for 24 weeks were divided into 2 groups according to age atomalizumabtreatmentonset:15to64yearsand65yearsorolder.Treatmentresponsewasassessedusing a 7-day urticaria activity score (UAS7). Adverse effects of omalizumab therapy were recorded. Results: Among patients, 32 (9.9%) were 65 years or older. At baseline, CSU characteristics were generally similar among the groups, although the presence of angioedema was statistically significantly lower in patients younger than 65 years. Any differences in weekly itch severity score, hive score, and UAS7 between the2agegroupswerenotsignificantatweeks4,12,and24,withtheexceptionof thehivescoreat24weeks and the UAS7 at week 24. No significant between-group differences were seen in the proportion of patients with a UAS7 of 6 or lower and with a UAS7 score of 0 at weeks 4, 12, 24, and 40. The proportion of patients with at least one adverse event reported as suspected to be caused by study drug was 10% in the younger group vs 6.3% in the older group (P=.53). Conclusion: Our study found that omalizumab is a well-tolerated and effective therapy for elderly patients with nonsedating H1-antihistamine–refractory CSU.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/531785
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 38
social impact